Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

68.31EUR
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
€68.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,768,060
52-wk High
€89.06
52-wk Low
€62.88

Select another date:
Photo

Latecomer Sanofi looks to catch next wave of cancer therapies

PARIS Sanofi missed the boat on immune system-boosting cancer drugs. Now it's trying to catch up.

Sanofi poaches former PSA finance boss Chasseloup de Chatillon

PARIS French drugmaker Sanofi announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA who had helped oversee a revival in PSA's fortunes.

UPDATE 1-Sanofi poaches former PSA finance boss Chasseloup de Chatillon

* Sanofi has been on takeover trail of late (Adds detail, background)

Sanofi poaches former PSA finance boss Chasseloup de Chatillon

PARIS, June 19 French drugmaker Sanofi announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA, to take up a similar position within Sanofi.

Study confirms higher risk of dengue in kids who got Sanofi vaccine

CHICAGO An analysis of data on Sanofi's dengue vaccine, which has been given to more than 800,000 school children in the Philippines, confirms it increases the risk of hospitalization and severe dengue in those who had never previously been infected with the mosquito-borne virus.

Study confirms higher risk of dengue in kids who got Sanofi vaccine

CHICAGO, June 13 An analysis of data on Sanofi's dengue vaccine, which has been given to more than 800,000 school children in the Philippines, confirms it increases the risk of hospitalization and severe dengue in those who had never previously been infected with the mosquito-borne virus.

BRIEF-Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 Diabetes

* FDA TO REVIEW ZYNQUISTA™ (SOTAGLIFLOZIN) AS POTENTIAL TREATMENT FOR TYPE 1 DIABETES

BRIEF-Sanofi announes some positive Phase 3 trials for Dupixent® (dupilumab)

* Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients

* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS

Sanofi/Regeneron cut Praluent drug price in Express Scripts deal

May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.

Select another date: